Application of the sG8 Scale in Real-World Geriatric Oncology Patients
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Geriatric Screening using the sG8 scale.
- Who it may be relevant to
- Registry conditions: Solid Cancers, Geriatric Assessment. Basic parameters: from 65 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This study is a multicenter, prospective, observational study. The study included patients aged 65 and older with solid tumors requiring systemic anti-tumor therapy. All patients underwent screening using the sG8 scale before the start of treatment, followed by routine treatment based on a plan developed through clinician decision-making. The study did not intervene in any way with the patients' diagnosis and treatment, and relevant clinical data during the treatment process were recorded accurately for follow-up patients. Study data were obtained from the electronic medical record databases and hospital information systems of multiple centers, including Sichuan Cancer Hospital. Patient clinicopathological features, pathological diagnoses, clinical stages, previous treatment histories, as well as anti-tumor treatment regimens after patient enrollment, drug dosages per cycle, treatment start times, incidence and grades of adverse events (AEs), and tumor response were extracted and collected from the medical records. All data were entered, managed, quality-controlled, exported, and analyzed through a real-world data management platform (RWDMP).
Interventions
- Other Geriatric Screening using the sG8 scale
Geriatric screening using the sG8 scale
Primary outcome measures
- The incidence of unplanned treatment delays and treatment interruptions [Time frame: From date receiving anti-tumor therapy after the first screening assessment until date of disease progression or death or the end of study, whichever came first, assessed up to 12 months]
Secondary outcome measures (3)
- TRAE [Time frame: From date receiving anti-tumor therapy after the first screening assessment until date of disease progression or death or the end of study, whichever came first, assessed up to 12 months]
- ORR [Time frame: From date receiving anti-tumor therapy after the first screening assessment until date of disease progression or death or the end of study, whichever came first, assessed up to 12 months]
- PFS [Time frame: From date receiving anti-tumor therapy after the first screening assessment until date of disease progression or death or the end of study, whichever came first, assessed up to 12 months.]
Eligibility criteria
Inclusion criteria
- Patients aged 65 years or older.
- Patients with confirmed malignant tumors based on definitive pathological data.
- Patients who are assessed by clinicians to have indications for systemic anti-tumor therapy.
- Patients with a survival time greater than 12 weeks.
Exclusion criteria
- Patients who do not meet the above inclusion criteria or are considered unsuitable for this study by the investigator due to other circumstances.
- Patients who are unwilling to cooperate in completing the sG8 scale assessment.
- Patients who do not understand the content of this study or are unwilling to participate.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT06939764 · EK2025-SG8